Kilcolman Industrial Supply, a lower-middle-market industrial distributor, carries a $69,300,000 headline enterprise value in Strathfell Capital Partners' letter of intent: 7.5 times a $9,240,000 adjusted EBITDA. Three findings price out against those exact terms. A $340,000 add-back for consulting fees that two years of recurring invoices disqualify from a quality-of-earnings review: $2,550,000 at the deal's own multiple. An unsubstantiated federal research credit spanning three tax years: $285,000 at its face amount. A customer contract requiring consent to assign: $6,300,000. The three sum to $9,135,000, 13.2 percent of the deal.
Page one for 'exit process checklist private equity' is a checklist ordered financial, then commercial, then legal and tax. Every result tells a seller what to look at; none assigns a dollar figure, so findings get fixed in whatever order a table of contents lists them, not the order that protects the most value. The gap has an arithmetic answer. Price an earnings-quality finding, the kind normalizing a target's EBITDA exists to catch, at the amount in question times the deal's own multiple. Price a liability at its direct dollar exposure, no multiple applied.
The customer contract is the case that matters most. Ellerslie Regional Utilities is 9.09 percent of Kilcolman's revenue, and the same concentration a buyer's commercial diligence prices becomes a specific consent requirement under an asset-deal structure. Priced at its EBITDA contribution times the multiple: $6,300,000, 69 percent of the total at risk, filed under 'commercial,' after 'financial statement integrity,' on a category-first checklist. The R&D credit uses the other basis: the IRS's four-part test has to be met for each claimed year, or the credit is owed back at face value, no multiple applied.